Allergan plc
AGN.PRA
AGN.PRA was delisted on the 28th of February, 2018.
117 hedge funds and large institutions have $3.14B invested in Allergan plc in 2016 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 30 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
33% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 30
8% more funds holding
Funds holding: 108 → 117 (+9)
5% less capital invested
Capital invested by funds: $3.31B → $3.14B (-$163M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$76.2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$38.9M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$34.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$34.6M |
| 5 |
SC
Sculptor Capital
New York
|
+$33.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$73M |
| 2 |
SG Americas Securities
New York
|
-$60.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$55.7M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$44.7M |
| 5 |
VSI
Verde Servicos Internacionais
Sao Paulo,
Brazil
|
-$24.3M |
AGN.PRA Hedge Fund Activity: Q3 2016 in Review
117 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN.PRA) for Q3 2016, worth a combined $3.14B — down 4.9% from $3.31B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AGN.PRA positions and 10 closed out — a net gain of 13 holders — while 40 added to existing stakes and 30 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $76.2M. The largest seller was Oaktree Capital Management, cutting an estimated $73M.
- 117 institutional investors held Allergan plc (AGN.PRA) as of Q3 2016, up from 108 in Q2 2016.
- Funds reported $3.14B of Allergan plc stock for Q3 2016, down 4.9% quarter-over-quarter.
- 23 funds opened new Allergan plc positions in Q3 2016 and 10 closed out, a net change of +13 holders.
- The largest Allergan plc buyer in Q3 2016 was OrbiMed, an estimated $76.2M added.
- The largest Allergan plc seller in Q3 2016 was Oaktree Capital Management, an estimated $73M sold.
Based on aggregated 13F filings for Q3 2016.